Dataset from Age Escalation / De-escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of a Radiation-attenuated Plasmodium Falciparum (Pf) Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults, Children and Infants, and Comparison With Non-attenuated Pf Sporozoites (PfSPZ Challenge) Administered Under Chloroquine Prophylaxis (PfSPZ-CVac Approach) for Efficacy Against Controlled Human Malaria Infection.

This trial will evaluate the safety, tolerability, and immunogenicity of PfSPZ Vaccine in
healthy Equatoguinean adults, adolescents, children and infants who receive doses of
0.9x10^6, 1.8x10^6 or 2.7x10^6 PfSPZ Vaccine via direct venous inoculation (DVI) compared
with control groups receiving normal saline (NS) placebo by DVI. In addition, the study will
also assess a second PfSPZ-based vaccination approach known as PfSPZ-CVac- the administration
of non-irradiated, infectious PfSPZ (PfSPZ Challenge) (1x10^5 PfSPZ) under anti-malarial
chemoprophylaxis (chloroquine) in younger adults ages 18 to 35 years for safety,
tolerability, immunogenicity and efficacy against controlled human malaria infection (CHMI).